RAPT / RAPT Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Form of Restricted Stock Unit Award Agreement and Grant Notice for RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 10.3 RAPT THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all o

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.5 RAPT Therapeutics, Inc. Non-Employee Director Compensation Policy July 9, 2025 Each member of the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation Pol

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan

Exhibit 10.4 RAPT THERAPEUTICS, INC. AMENDED AND RESTATED 2019 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 25, 2025 APPROVED BY THE STOCKHOLDERS: MAY 29, 2025 EFFECTIVE DATE: MAY 29, 2025 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares o

RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 10.1 APPENDIX B RAPT THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 25, 2025 APPROVED BY THE STOCKHOLDERS: May 29, 2025 EFFECTIVE DATE: May 29, 2025 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Company’s 2019 Equity Incentive Plan (the “Prior Plan”). From and after 12:01

Form of Stock Option Agreement and Grant Notice for RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 10.2 RAPT THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Optio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif. – August 7, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reporte

Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected

THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JULY 2025 Exhibit 99.1 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of data therefrom an

FORM 8-K Item 7.01 Regulation FD Disclosure.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 4.5 RAPT THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 25, 2025 APPROVED BY THE STOCKHOLDERS: MAY 29, 2025 EFFECTIVE DATE: MAY 29, 2025 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Company’s 2019 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Pacifi

Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the Inducement Plan

EX-4.10 Exhibit 4.10 RAPT THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (INDUCEMENT PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice

As filed with the Securities and Exchange Commission on June 20, 2025

As filed with the Securities and Exchange Commission on June 20, 2025 Registration No.

Form of Stock Option Agreement and Grant Notice for RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 4.6 RAPT THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option

RAPT Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan

Exhibit 4.8 RAPT THERAPEUTICS, INC. AMENDED AND RESTATED 2019 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 25, 2025 APPROVED BY THE STOCKHOLDERS: MAY 29, 2025 EFFECTIVE DATE: MAY 29, 2025 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of

Form of Restricted Stock Unit Award Agreement and Grant Notice for RAPT Therapeutics, Inc. 2025 Equity Incentive Plan

Exhibit 4.7 RAPT THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2025 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2025 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of

Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Inducement Plan

Exhibit 4.11 RAPT THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (INDUCEMENT PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and condit

RAPT Therapeutics, Inc. Inducement Plan

Exhibit 4.9 RAPT THERAPEUTICS, INC. INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 25, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RAPT Therapeutics, Inc.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

Certificate of Amendment of the Amended and Restated Certificate of Incorporation

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAPT THERAPEUTICS, INC. RAPT Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: First: The name of the Company is RAPT Therapeutics, Inc. (the “Company”). Second: The date of filing of the original

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected

THE SCIENCE TO OVERCOME INFLAMMATION CORPORATE PRESENTATION JUNE 2025 Exhibit 99.1 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the development of RPT904, including the expected timing of clinical trials and the availability of data therefrom an

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

FORM 8-K Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

RAPT Therapeutics Reports First Quarter 2025 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif. – May 8, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported fi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Inducement Plan

Exhibit 10.3 RAPT Therapeutics, Inc. Restricted Stock Unit Grant Notice (Inducement Plan) RAPT Therapeutics, Inc. (the “Company”), pursuant to its Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms and condit

Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the Inducement Plan

Exhibit 10.2 RAPT Therapeutics, Inc. Stock Option Grant Notice (Inducement Plan) RAPT Therapeutics, Inc. (the “Company”), pursuant to its Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the

RAPT Therapeutics, Inc. Inducement Plan

Exhibit 10.1 RAPT THERAPEUTICS, INC. INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 25, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif. – March 6, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RAPT Therapeutics, Inc.

Form of Stock Option Agreement and Grant Notice for RAPT Therapeutics, Inc. 2019 Equity Incentive Plan

Exhibit 4.5 RAPT THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2019 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock Option

RAPT Therapeutics, Inc. 2019 Equity Incentive Plan

Exhibit 4.4 RAPT THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 27, 2019 APPROVED BY THE STOCKHOLDERS: JULY 18, 2019 IPO DATE: OCTOBER 30, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Company’s 2015 Stock Plan (the “Prior Plan”). From and after 12:01 a.m. Pacific time on the

As filed with the Securities and Exchange Commission on March 6, 2025

As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.

RAPT Therapeutics, Inc. 2019 Employee Stock Purchase Plan

Exhibit 4.7 RAPT THERAPEUTICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 27, 2019 APPROVED BY THE STOCKHOLDERS: JULY 18, 2019 IPO DATE: OCTOBER 30, 2019 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan

Insider Trading Policy

Exhibit 19.1 RAPT Therapeutics, Inc. Insider Trading and Trading Window Policy June 27, 2019 Because our stock is publicly traded, you must comply with the provisions of federal and state securities laws and with our policies. During the course of your relationship with RAPT Therapeutics, Inc. (the “Company”), you will learn information about us that is not publicly known. It is illegal for you to

Form of Restricted Stock Unit Award Agreement and Grant Notice for RAPT Therapeutics, Inc. 2019 Equity Incentive Plan

Exhibit 4.6 RAPT THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2019 EQUITY INCENTIVE PLAN) RAPT Therapeutics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of

176,452,000 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284388 PROSPECTUS 176,452,000 Shares of Common Stock This prospectus relates to the offer and resale by the selling stockholders identified in this prospectus or their donees, pledgees, assignees, transferees, distributees or other successors-in-interest (the “selling stockholders”) of up to an aggregate of 176,452,000 shares

RAPT THERAPEUTICS, INC. 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

RAPT THERAPEUTICS, INC. 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000 January 23, 2025 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 RE: RAPT Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-284388) Request for Acceleration of Effective Date Ladies and Gentlem

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) RAPT Therapeutics, Inc.

As filed with the Securities and Exchange Commission on January 21, 2025

S-3 Table of Contents As filed with the Securities and Exchange Commission on January 21, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissio

January 2025 Corporate Presentation

January 2025 Corporate Presentation Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements.

Joint Filing Agreement

EX-99.1 2 ex991to13g07422rapt010625.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 6, 2025 with respect to the Common Stock, $0.0001 par value per share, of RAPT Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on beh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2025 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissio

Form of Registration Rights Agreement

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 23, 2024, is entered into by and among RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms

Form of Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38997), filed with the SEC on December 23, 2024).

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 23, 2024, by and among RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliverin

RAPT Therapeutics Announces $150 Million Private Placement

EX-99.2 Exhibit 99.2 RAPT Therapeutics Announces $150 Million Private Placement SOUTH SAN FRANCISCO, Calif. – December 23, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases , today announced that it has entere

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 mill

EX-99.1 Exhibit 99.1 RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducti

License Agreement, dated December 22, 2024, by and between RAPT Therapeutics, Inc. and Shanghai Jemincare Pharmaceutical Co., Ltd

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans; curre

EX-99.3 December 23, 2024 Corporate Presentation Exhibit 99.3 Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans; current and future drug candidates, including the in-license of RPT904 (JYB-1904); the licens

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 RAPT Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

Form of Pre-Funded Warrant and Exchange Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THIS SECURITY AND THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

RAPT / RAPT Therapeutics, Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-rapt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif. – November 12, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif. – August 8, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif. – May 9, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.1 RAPT Therapeutics, Inc. Non-Employee Director Compensation Policy March 27, 2024 Each member of the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑        Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material under § 240.

Amendment No. 2, dated February 1, 2024, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.

Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL Rapt Therapeutics AMENDMENT NO. 2 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This Amendment No. 1 (“Amendment No. 2”) to the Agreement (as defined below), is entered into a

Incentive Compensation Recoupment Policy

Exhibit 97 RAPT Therapeutics, Inc. Incentive Compensation Recoupment Policy October 23, 2023 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Reco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RAPT Therapeutics, Inc.

Power of Attorney. Reference is made to the signature page of this Registration Statement

S-8 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Company maintains solid cash position of $158.9 million

Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Company maintains solid cash position of $158.9 million SOUTH SAN FRANCISCO, Calif. – March 7, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with signific

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES of RAPT THERAPEUTICS, INC. (as of December 31, 2023) NAME OF SUBSIDIARY COUNTRY OF FORMATION None

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

Joint Filing Agreement

EX-99.1 2 tm245846d25ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001

RAPT / RAPT Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d638544dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E 109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

RAPT / RAPT Therapeutics, Inc. / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-rapt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che

AGREEMENT

EX-99.1 2 d638544dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

RAPT / RAPT Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm245846d25sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

RAPT / RAPT Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01783-rapttherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: RAPT Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 75382E109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuan

RAPT Therapeutics Reports Third Quarter 2023 Financial Results Company maintains strong cash position of $184.8 million

Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2023 Financial Results Company maintains strong cash position of $184.8 million SOUTH SAN FRANCISCO, Calif. – November 13, 2023 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC -Confirmed objective response rat

Exhibit 99.1 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC -Confirmed objective response rate (ORR) of 40% in PD-L1 positive patients (TPS ≥1%) with no prior checkpoint inhibitor therapy (CPI) -Median progression-free survival (P

RAPT / RAPT Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Up to $150,000,000 Common Stock

Table of Contents Filed Pursuant to 424(b)(5) Registration Statement No. 333-273910 PROSPECTUS Up to $150,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the sales agreement, with Cantor Fitzgerald & Co., or Cantor, and Leerink Partners LLC, or Leerink Partners, relating to shares of our common stock, $0.0001 par value per share, offered by this prospec

RAPT THERAPEUTICS, INC. 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

RAPT THERAPEUTICS, INC. 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000 August 15, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: RAPT Therapeutics, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273910 Ladies and Gentlemen: In accordance

RAPT Therapeutics Reports Second Quarter 2023 Financial Results Company maintains strong cash position of $205 million

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2023 Financial Results Company maintains strong cash position of $205 million SOUTH SAN FRANCISCO, Calif. – August 11, 2023 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet nee

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 RAPT Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

Controlled Equity OfferingSM Sales Agreement, dated August 11, 2023, between the Company and Cantor Fitzgerald & Co. and Leerink Partners LLC (incorporated by reference to Exhibit 1.2 to the Company’s Form S-3 (File No. 333-272910) filed with the SEC on August 11, 2023).

EX-1.2 Exhibit 1.2 RAPT Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 11, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: On the date hereof, RAPT Therapeutics, Inc., a Delaware corporation (the “Company”

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RAPT Therapeutics, Inc.

Form of Debt Indenture

EX-4.4 Exhibit 4.4 RAPT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 2023 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certific

Form of Preferred Stock Warrant Agreement and Warrant Certificate

EX-4.7 Exhibit 4.7 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.1 RAPT Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

Form of Common Stock Warrant Agreement and Warrant Certificate

EX-4.6 Exhibit 4.6 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exis

Form of Debt Securities Warrant Agreement and Warrant Certificate

EX-4.8 Exhibit 4.8 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized

Power of Attorney (See signature page)

S-3 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million SOUTH SAN FRANCISCO, Calif. – May 11, 2023 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material under § 240.

Schedule 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

As filed with the Securities and Exchange Commission on March 14, 2023

S-8 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No.

Amendment No. 1, dated April 20, 2022, to the Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.

Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL RAPT Therapeutics, Inc. (formerly FLX) AMENDMENT NO. 1 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This Amendment No. 1 (“Amendment No. 1”) to the Agreement (as defined belo

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million

Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – March 14, 2023 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES of RAPT THERAPEUTICS, INC. (as of December 31, 2022) NAME OF SUBSIDIARY COUNTRY OF FORMATION RAPT Therapeutics Australia Pty. Ltd Australia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RAPT Therapeutics, Inc.

Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "

Transforming the Treatment of Inflammation and Cancer Corporate Presentation March 2023 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT / Rapt Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236041d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the

AGREEMENT

EX-99.1 2 d423442dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

Joint Filing Agreement

EX-99.1 2 tm236041d10ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001

RAPT / Rapt Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d423442dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E 109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement)

RAPT / Rapt Therapeutics Inc / COLUMN GROUP II, LP - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415)

Joint Filing Statement

EX-99.A 2 d435922dex99a.htm EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Amendment No. 6 to Schedule 13D is filed on behalf of each of us. Dated: January 13, 2023 THE COLUMN GROUP II, LP THE COLUMN GROUP II GP, LP By: The Column Group II GP, LP By: /s/ James Evangelista, Attorney-in-Fact By: /s/ James Evangelista, Attorney-in-Fact PON

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the Company, we,

EX-99.1 2 d434788dex991.htm EX-99.1 Exhibit 99.1 Transforming the Treatment of Inflammation and Cancer January 2023 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the Company, we, or us ) re

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer Data Presented at ESMO Immuno-Oncology Congress

Exhibit 99.1 RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer Data Presented at ESMO Immuno-Oncology Congress SOUTH SAN FRANCISCO, Calif. ? December 8, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissio

Underwriting Agreement, dated November 17, 2022

Exhibit 1.1 EXECUTION VERSION RAPT THERAPEUTICS, INC. 4,054,055 Shares of Common Stock Underwriting Agreement November 17, 2022 J.P. MORGAN SECURITIES LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Evercore Group L.L.C. 55 East 52nd Street, 36th Floor New York, New Y

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

RAPT Therapeutics, Inc. Attn: Chief Financial Officer 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

Table of Contents Filed Pursuant to 424(b)(5) Registration Statement No. 333-249848 Prospectus Supplement (To Prospectus dated November 16, 2020) 4,054,055 shares Common stock We are offering 4,054,055 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?RAPT.? On November 17, 2022, the last reported sale price of our common stock was $21.31 per shar

RAPT Therapeutics, Inc. Attn: Chief Financial Officer 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

Table of Contents Filed Pursuant to 424(b)(5) Registration Statement No. 333-249848 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.1 RAPT Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the ?Board?) of RAPT Therapeutics, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT

RAPT Therapeutics Reports Third Quarter 2022 Financial Results Company maintains strong cash position of $195.4 million

Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2022 Financial Results Company maintains strong cash position of $195.4 million SOUTH SAN FRANCISCO, Calif. ? November 10, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation

Exhibit 99.1 Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.?s (the ?Company,? ?we,? or ?us?) research and clinical developme

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

RAPT Therapeutics Reports Second Quarter 2022 Financial Results Company maintains strong cash position of $207.3 million

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2022 Financial Results Company maintains strong cash position of $207.3 million SOUTH SAN FRANCISCO, Calif. ? August 11, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant un

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

4,000,000 shares Common stock

Table of Contents Filed Pursuant to 424 (b) (3) Registration Statement No. 333-265812 PROSPECTUS 4,000,000 shares Common stock This prospectus relates to the proposed resale from time to time of up to 4,000,000 shares (the ?Shares?) of our common stock, par value $0.0001 per share (the ?common stock?), which are issuable upon the exercise of pre-funded warrants to purchase shares of common stock (

RAPT Therapeutics, Inc. 561 Eccles Avenue South San Francisco, California, 94080

RAPT Therapeutics, Inc. 561 Eccles Avenue South San Francisco, California, 94080 June 27, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky Re: RAPT Therapeutics, Inc. Registration Statement on Form S-3 Filed June 24, 2022 File No. 333-265812 To whom it may concern: Pursuant t

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) RAPT Therapeutics, Inc.

As filed with the Securities and Exchange Commission on June 24, 2022

Table of Contents As filed with the Securities and Exchange Commission on June 24, 2022 Registration No.

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of RAPT Therapeutics, In

RAPT / Rapt Therapeutics Inc / Redmile Group, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) May 24, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

Form of Pre-Funded Warrant

Exhibit 4.1 FORM OF WARRANT THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1

Registration Rights Agreement, dated May 27, 2022, by and between RAPT Therapeutics, Inc. and the investor party thereto

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of May 27, 2022 by and among RAPT Therapeutics, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors (the ?Purchase Agreement?). Capitalized terms used herein have the

RAPT Therapeutics Announces Private Placement Financing of $50 Million

Exhibit 99.1 RAPT Therapeutics Announces Private Placement Financing of $50 Million SOUTH SAN FRANCISCO, Calif. ? May 25, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, toda

Securities Purchase Agreement, dated May 24, 2022, by and between RAPT Therapeutics, Inc. and the investor party thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of May 24, 2022 by and among RAPT Therapeutics, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. The Company and the Investors are executing and deliveri

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis

Exhibit 99.1 RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis SOUTH SAN FRANCISCO, Calif. ? May 23, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

RAPT Therapeutics Reports First Quarter 2022 Financial Results Company maintains strong cash position of $173.0 million

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2022 Financial Results Company maintains strong cash position of $173.0 million SOUTH SAN FRANCISCO, Calif. ? May 11, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet

Schedule 14A

DEFA14A 1 d339320ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14A-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RAPT Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

As filed with the Securities and Exchange Commission on March 10, 2022

As filed with the Securities and Exchange Commission on March 10, 2022 Registration No.

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES of RAPT THERAPEUTICS, INC. (as of December 31, 2021) NAME OF SUBSIDIARYCOUNTRY OF FORMATION RAPT Therapeutics Australia Pty. LtdAustralia

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Company maintains strong cash position of $189.7 million

Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results Company maintains strong cash position of $189.7 million SOUTH SAN FRANCISCO, Calif. ? March 10, 2022 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with si

AGREEMENT

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

RAPT / Rapt Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d240214dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E 109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement)

RAPT / Rapt Therapeutics Inc / Kleiner Perkins Caufield & Byers XV, LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75382E109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissio

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2021 Financial Results SOUTH SAN FRANCISCO, Calif. ? November 10, 2021 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today r

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commiss

Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "

Transforming the Treatment of Cancer and Inflammation Corporate Presentation September 2021 Exhibit 99.

RAPT / Rapt Therapeutics Inc / COLUMN GROUP II, LP - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415)

Joint Filing Statement

EX-99.A 2 d228636dex99a.htm EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Amendment No. 5 to Schedule 13D is filed on behalf of each of us. Dated: September 20, 2021 THE COLUMN GROUP II, LP THE COLUMN GROUP II GP, LP By: The Column Group II GP, LP By: /s/ James Evangelista, Attorney-in-Fact By: /s/ James Evangelista, Attorney-in-Fact P

RAPT / Rapt Therapeutics Inc / COLUMN GROUP II, LP - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Francisco, CA 94129 (415) 865-2050

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

RAPT Therapeutics Reports Second Quarter 2021 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2021 Financial Results SOUTH SAN FRANCISCO, Calif. ? August 11, 2021 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today re

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

RAPT Therapeutics, Inc. Attn: Chief Financial Officer 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

Table of Contents Filed Pursuant to Rule 424(b)(5)Registration No. 333-249848 Prospectus Supplement (To Prospectus dated November 16, 2020) 3,787,879 shares Common stock We are offering 3,787,879 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?RAPT.? On June 15, 2021, the last reported sale price of our common stock was $35.19 per share. We are

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

Underwriting Agreement, dated June 15, 2021

EX-1.1 2 d193657dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION RAPT THERAPEUTICS, INC. 3,787,879 Shares of Common Stock Underwriting Agreement June 15, 2021 J.P. MORGAN SECURITIES LLC SVB LEERINK LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Leerink LLC 255 Califo

RAPT Therapeutics, Inc. Attn: Chief Financial Officer 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000

Table of Contents Filed Pursuant to Rule 424(b)(5)Registration No. 333-249848 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these secur

RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis – Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four

Exhibit 99.1 RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis ? Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once - daily oral treatment with RPT193 ? Further improvement in percent change in EASI, EASI-50 and vIGA observed with

Transforming the Treatment of Cancer and Inflammation RPT193 Topline Results June 14, 2021 Exhbit 99.2

EX-99.2 3 d181504dex992.htm EX-99.2 Transforming the Treatment of Cancer and Inflammation RPT193 Topline Results June 14, 2021 Exhbit 99.2 Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we," or "us

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission F

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

Quarterly Report - 10-Q 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission Fi

RAPT Therapeutics Reports First Quarter 2021 Financial Results

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2021 Financial Results SOUTH SAN FRANCISCO, Calif. ? May 11, 2021 ? RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today report

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte

- S-8

As filed with the Securities and Exchange Commission on March 11, 2021 Registration No.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commission

RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results

EX-99.1 2 d151181dex991.htm EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results SOUTH SAN FRANCISCO, Calif. – March 11, 2021 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* RAPT Therapeutics, In

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75382E109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E 109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* RAPT Therapeutics, Inc (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Dece

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPT Therapeutics, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75382E109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Sec

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75382E 109 (CUSIP Number) December 4, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design

RAPT Therapeutics Reports Third Quarter 2020 Financial Results

EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Third Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. – November 16, 2020 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases,

Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "

EX-99.3 4 d86412dex993.htm EX-99.3 Transforming the Treatment of Cancer and Inflammation FLX475 Clinical Data Update November 16, 2020 Exhibit 99.3 Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the "Company," "we

RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications -Evidence of Monotherapy and Combination Activity in Charged Tumor Types- -Company Advances Several Cohorts into Phase 2 Ex

EX-99.2 Exhibit 99.2 RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications -Evidence of Monotherapy and Combination Activity in Charged Tumor Types- -Company Advances Several Cohorts into Phase 2 Expansions- -Conference Call and Webcast to be Held at 8:30 a.m. ET Today- SOUTH SAN FRANCISCO, Calif. – November 16, 2020 – RAPT T

Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT

-

CORRESP RAPT THERAPEUTICS, INC. 561 Eccles Avenue South San Francisco, California 94080 (650) 489-9000 November 10, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: RAPT Therapeutics, Inc. Registration Statement on Form S-3 Filed November 4, 2020 File No. 333-249848 Ladies and Gentl

Form of Common Stock Warrant Agreement and Warrant Certificate

EX-4.6 4 d41514dex46.htm EX-4.6 Exhibit 4.6 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking associ

Form of Debt Securities Warrant Agreement and Warrant Certificate

EX-4.8 Exhibit 4.8 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized

Form of Debt Indenture

EX-4.4 Exhibit 4.4 RAPT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms. 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities. 5 Section 2.02 Form of Securities and Trustee’s Certific

Controlled Equity OfferingSM Sales Agreement, dated November 4, 2020, between the registrant and Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated

EX-1.2 Exhibit 1.2 RAPT Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement November 4, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Stifel, Nicolaus & Company, Incorporated 787 7th Avenue, 11th Floor New York, NY 10019 Ladies and Gentlemen: RAPT Therapeutics, Inc., a Delaware corporation (the “Company”), confirms

Form of Preferred Stock Warrant Agreement and Warrant Certificate

EX-4.7 Exhibit 4.7 RAPT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF RAPT THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between RAPT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized

- S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on November 4, 2020 Registration No.

RAPT / RAPT Therapeutics, Inc. / COLUMN GROUP II, LP - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name,

RAPT / RAPT Therapeutics, Inc. / COLUMN GROUP II, LP - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name,

Joint Filing Statement

EX-99.A 2 d946263dex99a.htm EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Amendment No. 2 to Schedule 13D is filed on behalf of each of us. Dated: August 26, 2020 THE COLUMN GROUP II, LP THE COLUMN GROUP II GP, LP By: The Column Group II GP, LP By: /s/ Jennifer J. Carlson, Attorney-in-Fact By: /s/ Jennifer J. Carlson, Attorney-in-Fact

RAPT Therapeutics Reports Second Quarter 2020 Financial Results

EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. – August 13, 2020 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases,

Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commis

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Thera

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissi

RAPT / RAPT Therapeutics, Inc. / Topspin Fund, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPT Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) May 26, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

RAPT Therapeutics Reports First Quarter 2020 Financial Results

EX-99.1 2 d932386dex991.htm EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. – May 14, 2020 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT Ther

Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commissio

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Schedule 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

RAPT / RAPT Therapeutics, Inc. S-8 - - S-8

S-8 As filed with the Securities and Exchange Commission on March 30, 2020 Registration No.

Amended and Restated Non-Employee Director Compensation Policy

Exhibit 10.14 RAPT Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy September 26, 2019 Each member of the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Co

RAPT / RAPT Therapeutics, Inc. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (

Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 RAPT Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38997 47-3313701 (State or Other Jurisdiction of Incorporation) (Commiss

Offer Letter, by and between Karen Lam and RAPT Therapeutics, Inc., dated July 10, 2019

Exhibit 10.13 July 10, 2019 Karen Lam Dear Karen, This letter agreement (the “Agreement”) sets forth the terms and conditions of your continued employment with RAPT Therapeutics, Inc. (“RAPT” or the “Company”). This Agreement supersedes and replaces all prior written employment agreements, offer letters, or oral promises regarding the subject matter herein, including, but not limited to, your init

RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update — Company bolsters cash by $116 million with public offerings in late 2019 and early 2020 —

EX-99.1 Exhibit 99.1 RAPT Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Business Update — Company bolsters cash by $116 million with public offerings in late 2019 and early 2020 — SOUTH SAN FRANCISCO, Calif. – March 30, 2020 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commerc

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Registra

RAPT / RAPT Therapeutics, Inc. / REGENTS OF THE UNIVERSITY OF CALIFORNIA - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RAPT Therapeutics, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 75382E109 (CUSIP Number) 1111 Broadway, Suite 2100, Oakland, CA 94607 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Decem

RAPT / RAPT Therapeutics, Inc. / Column Group Ii, Lp - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* RAPT THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 75382E 109 (CUSIP Number) Peter Svennilson The Column Group II, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name,